Purdue files petition to delay generic versions of OxyContin

01/13/2004 | NYTimes.com

Purdue Pharma, maker of the painkiller OxyContin, has filed a petition with federal regulators asking for a further delay of generic versions. The drug maker contends that the FDA should not approve generics until their makers develop plans to halt the abuse of the drug. The state of Connecticut is investigating Purdue for potential antitrust violations and a consumer group has sued the company on the same charge.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY